Bavarian Nordic A/S $ 11.90 0.55 (4.85%)
Volume:
3,500
Avg Vol (1m):
1,835
Market Cap $:
2.08 Bil
Enterprise Value $:
1.74 Bil
PE Ratio:
14.42
PB Ratio:
2.04
Current and historical daily P/E ratio for Bavarian Nordic A/S () from 2013 to Mar 06 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Bavarian Nordic A/S stock (BVNRY) PE ratio as of Mar 06 2021 is 14.42.
More Details
Bavarian Nordic A/S PE Ratio (TTM) Chart
EMBED
Bavarian Nordic A/S PE Ratio (TTM) Historical Data
View and export this data going back to 2013. Start your Free Trial
Total 1244
- 1
- 2
- 3
- 4
- 5
- 6
- 14
Bavarian Nordic A/S PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2021-03-06 | 17.0 | 2020-12-30 | 15.3 |
2021-03-05 | 17.0 | 2020-12-29 | 15.3 |
2021-03-04 | 16.2 | 2020-12-28 | 15.3 |
2021-03-03 | 16.2 | 2020-12-24 | 15.4 |
2021-03-02 | 16.2 | 2020-12-23 | 15.4 |
2021-03-01 | 16.2 | 2020-12-22 | 15.4 |
2021-02-26 | 18.3 | 2020-12-21 | 16.0 |
2021-02-25 | 19.6 | 2020-12-18 | 16.0 |
2021-02-24 | 19.6 | 2020-12-17 | 16.1 |
2021-02-23 | 19.6 | 2020-12-16 | 16.1 |
2021-02-22 | 19.6 | 2020-12-15 | 15.0 |
2021-02-19 | 20.3 | 2020-12-14 | 13.8 |
2021-02-18 | 20.3 | 2020-12-11 | 13.8 |
2021-02-17 | 20.3 | 2020-12-10 | 13.8 |
2021-02-16 | 20.3 | 2020-12-09 | 13.8 |
2021-02-12 | 20.3 | 2020-12-08 | 13.8 |
2021-02-11 | 20.3 | 2020-12-07 | 14.1 |
2021-02-10 | 20.0 | 2020-12-04 | 14.1 |
2021-02-09 | 20.0 | 2020-12-03 | 14.1 |
2021-02-08 | 20.0 | 2020-12-02 | 13.1 |
2021-02-05 | 18.1 | 2020-12-01 | 13.1 |
2021-02-04 | 18.1 | 2020-11-30 | 13.1 |
2021-02-03 | 18.1 | 2020-11-27 | 13.1 |
2021-02-02 | 18.1 | 2020-11-25 | 13.1 |
2021-02-01 | 16.6 | 2020-11-24 | 13.1 |
2021-01-29 | 16.6 | 2020-11-23 | 13.1 |
2021-01-28 | 16.7 | 2020-11-20 | 13.1 |
2021-01-27 | 16.7 | 2020-11-19 | 13.1 |
2021-01-26 | 16.7 | 2020-11-18 | 13.1 |
2021-01-25 | 16.7 | 2020-11-17 | 13.1 |
2021-01-22 | 16.7 | 2020-11-16 | 13.1 |
2021-01-21 | 16.7 | 2020-11-13 | 13.8 |
2021-01-20 | 16.7 | 2020-11-12 | 13.8 |
2021-01-19 | 16.7 | 2020-11-11 | 13.8 |
2021-01-15 | 16.7 | 2020-11-10 | 13.8 |
2021-01-14 | 16.1 | 2020-11-09 | 13.8 |
2021-01-13 | 15.0 | 2020-11-06 | 13.2 |
2021-01-12 | 15.0 | 2020-11-05 | 13.2 |
2021-01-11 | 15.0 | 2020-11-04 | 13.2 |
2021-01-08 | 15.0 | 2020-11-03 | 13.2 |
2021-01-07 | 15.3 | 2020-11-02 | 13.2 |
2021-01-06 | 15.3 | 2020-10-30 | 13.2 |
2021-01-05 | 15.3 | 2020-10-29 | 13.2 |
2021-01-04 | 15.3 | 2020-10-28 | 13.2 |
2020-12-31 | 15.3 | 2020-10-27 | 14.8 |
Bavarian Nordic A/S PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
Compare
OCSE:ZEAL
OCSE:ALK B
OCSE:ORPHA
OCSE:NOVO B
ASX:CSL
NAS:VRTX
NAS:REGN
XKRX:207940
NAS:SGEN
NAS:MRNA
NAS:ALXN
XKRX:068270
NAS:INCY
HKSE:02269
OCSE:GMAB
HKSE:01177
SZSE:300122
NAS:BMRN
XBRU:UCB
NAS:ALNY
Address
Hejreskovvej 10A, Kvistgaard, DNK, 3490
Bavarian Nordic is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the Netherlands, followed by the United States, Canada, and other geographic markets.